Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02604264 · ClinicalTrials.gov registry record · NA
Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
A NA study of End Stage Renal Disease (ESRD), sponsored by Pursuit Vascular.
- Completed
- Registry status
- NA
- Development phase
- 2,912
- Enrollment target
- 1
- Study location
NCT02604264: Completed NA study of End Stage Renal Disease (ESRD), sponsored by Pursuit Vascular.
NCT02604264 is a NA study of End Stage Renal Disease (ESRD) that has completed, run by Pursuit Vascular. The registered enrollment target is 2,912 participants, above the 85-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (3326% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02604264, a NA study of End Stage Renal Disease (ESRD), has completed, sponsored by Pursuit Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,912 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess positive blood cultures (PBCs) in hemodialysis central venous catheter (CVC) patients using two FDA cleared devices: ClearGuard HD end caps compared to conventional end caps.
Primary Outcome
This was calculated by dividing the cumulative number of PBCs by cumulative time at-risk as follows. The National Healthcare Safety Network (NHSN) Center for Disease Control (CDC) 21-day outpatient hemodialysis patient rule is as follows: A PBC is considered a new event and counted only if it occurred 21 days or more after a previously reported PBC in the same patient; new PBC events are based on blood cultures drawn as an outpatient or within one calendar day after a hospital admission. Follow
Conditions Studied
Interventions
- DEVICE ClearGuard HD end cap
Study Locations (1)
Massachusetts
- Frenova Renal Research - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,912 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-11 |
| Phase | NA |
What the finished NCT02604264 record still lists
NCT02604264 is an interventional study that assigns participants to a tested intervention. Its 2,912 participants enrollment target places it among the larger protocols in the corpus, above the 85-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (3326% higher).
The record links to 1 condition, with End Stage Renal Disease (ESRD) appearing as the primary indexed condition, and to 1 intervention - of which ClearGuard HD end cap is the first listed.
NCT02604264 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02604264 about?
NCT02604264 is a clinical study titled "Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap". To assess positive blood cultures (PBCs) in hemodialysis central venous catheter (CVC) patients using two FDA cleared devices: ClearGuard HD end caps compared to conventional end caps.
What is the current status of trial NCT02604264?
This trial is currently completed. It is a NA study. The enrollment target is 2,912 participants. The study started on 2014-12. Estimated completion is 2015-11.
What conditions does trial NCT02604264 study?
This clinical trial studies the following conditions: End Stage Renal Disease (ESRD).
What interventions are being tested in trial NCT02604264?
The interventions under investigation include: ClearGuard HD end cap (DEVICE).
Who is sponsoring clinical trial NCT02604264?
This trial is sponsored by Pursuit Vascular, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02604264 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease (ESRD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02604264's enrollment target sits among peer trials
2,912 1st of 10 higher than 10 of 10 other End Stage Renal Disease (ESRD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease (ESRD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
RECRUITING · NA
-
Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access
ACTIVE NOT RECRUITING · NA
-
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
RECRUITING · Phase 3
-
EndoForce Post Approval Study
RECRUITING
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05564377 · 2,900 participants · Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- NCT07222995 · 2,900 participants · NA
Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
- NCT06273436 · 2,894 participants · NA
Healing, Equity, Advocacy and Respect for Mamas
- NCT05849961 · 2,946 participants
Exactech Hip Systems Post-Market Clinical Follow-up (PMCF)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia